UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

For the quarterly period ended: March 31, 2019

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ____________

Commission File Number: 001-36604

~~For the transition period from ________ to _________ Commission File Number 001-36604~~ BIOSCIENCE NEUTRACEUTICALS, INC. ~~f/k/a JOBLOCATION MAP INC.~~ (Exact name of registrant as specified in its charter)

Nevada

46-0745348

(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

500 North Michigan Avenue #600, Chicago IL

60611

(Address of principal executive offices)

(Zip Code)

773-236-8132 ~~(Registrant’s telephone number, including area code)~~

~~N/A~~ (~~Former~~Registrant’s ~~name,~~telephone ~~former address and former fiscal year~~number, ifincluding ~~changed~~area ~~since last report~~code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x YES ¨ NO Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x YES ¨ NO Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.N/A

~~Large~~(Former ~~accelerated~~name, ~~filer~~former ¨address ~~Accelerated~~and ~~filer~~former ¨fiscal ~~Non-accelerated~~year, ~~filer ¨ (Do not check~~ if achanged ~~smaller~~since ~~reporting~~last ~~company~~report) ~~Smaller reporting company x Emerging growth company ¨~~

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ Indicate by check mark whether the registrant ~~is a shell company~~ (~~as defined in Rule 12b-2 of the Exchange Act~~1) ~~¨ YES x NO APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS Check whether the registrant~~ has filed all ~~documents and~~ reports required to be filed by ~~Sections~~Section ~~12,~~ 13 or 15(d) of the Securities Exchange Act ~~after the distribution~~ of ~~securities~~1934 ~~under~~during athe ~~plan~~preceding ~~confirmed~~12 bymonths a(or ~~court.~~for ¨such ~~YES~~shorter ¨period NOthat ~~APPLICABLE ONLY TO CORPORATE ISSUERS Indicate~~ the ~~number~~registrant ofwas ~~shares~~required ~~outstanding~~to offile ~~each~~such ~~of the issuer’s classes of common stock~~reports), asand of(2) ~~the~~has ~~latest~~been ~~practicable~~subject ~~date.~~to ~~9,700,000~~such ~~common~~filing ~~shares~~requirements ~~issued~~for ~~and~~the ~~outstanding~~past as90 ~~of November 19, 2018~~days. x YES ¨ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x YES ¨ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ¨ YES x NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ¨ YES ¨ NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

8,042,516 common shares issued and outstanding as of May 10, 2019.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	3	3
Item 2.	Management's Discussion and Analysis of Financial Condition or Plan of Operation	10	10
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13	14
Item 4.	Controls and Procedures	13	14
PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	14	15
Item 1A.	Risk Factors	14	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14	15
Item 3.	Defaults Upon Senior Securities	14	15
Item 4.	Mine Safety Disclosures	14	15
Item 5.	Other Information	14	15
Item 6.	Exhibits	14	16
SIGNATURES		15

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

BIOSCIENCE NEUTRACEUTICALS, INC.

~~(Formerly~~BALANCE ~~JOBLOCATIONMAP INC.)~~SHEETS

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	September 30,			December 31,
	March 31,			December 31,
	2018			2017
	2019			2018
ASSETS
Current Assets
Cash and cash equivalents	$	1,088		$	1,488
Prepaid expense	$	-		$	6,000
Inventory		4,916			3,201
Total Current Assets		-			6,000
Total Current Assets		6,004			4,689
Total Assets	$	-		$	6,000
Total Assets	$	6,004		$	4,689
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued liabilities		2848,~~388~~750			836,~~576~~813
Due to related parties		~~102~~107,~~556~~420			75100,~~279~~172
Convertible notes		2214,878			22,878
Notes payable		27,500			27,500
Total Current Liabilities		~~181~~198,~~322~~548			~~134~~187,~~233~~363
Long-term note payable		3,957			-3,957
Total Liabilities		~~185~~202,~~279~~505			~~134~~191,~~233~~320
STOCKHOLDERS' DEFICIT
Preferred Stock, par value $0.0001, 50,000,000 shares authorized, 0 shares issued and outstanding, respectively		-			-
Common Stock, par value $0.0001, 100,000,000 shares authorized, 9,700,000 shares issued and outstanding, respectively		970			970
Common Stock, par value $0.0001, 100,000,000 shares authorized, 8,042,516 and 242,516 shares issued and outstanding, respectively		804			24
Additional paid-in capital		~~114~~562,~~215~~055			~~114~~132,~~215~~923
Accumulated deficit		(~~294~~765,~~460~~364	)		(~~244~~318,~~729~~267	)
Total Stockholders' Deficit		(~~179~~202,~~275~~505	)		(~~129~~185,~~544~~320	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	~~6,004~~-		$	46,~~689~~000

The accompanying notes are an integral part of these ~~consolidated~~ financial statements.

Table of Contents

BIOSCIENCE NEUTRACEUTICALS, INC.

~~(Formerly~~STATEMENTS ~~JOBLOCATIONMAP~~OF ~~INC.)~~OPERATIONS

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended						For the Nine Months Ended
	Three Months Ended
	September 30,						September 30,
	March 31,
	2018			2017			2018			2017
	2019			2018
Revenues	$	~~1,693~~-		$	~~4,318~~-		$	~~6,163~~		$	~~4,318~~
Cost of Goods Sold		1,859			3,518			8,257			3,518
Operating Expenses
Gross Profit		(166	)		800			(2,094	)		800
General and administration		382			-
Operating Expenses
Professional		18,625			1,488
General and administration		1,435			1,495			5,905			2,728
Stock based compensation		421,912			-
Professional		2,950			15,200			23,207			19,450
Total operating expenses		440,919			1,488
Total operating expenses		4,385			16,695			29,112			22,178
Net loss from operations		(440,919	)		(1,488	)
Net loss from operations		(4,551	)		(15,895	)		(31,206	)		(21,378	)
Other expense
Other expense
Interest expense		(6,178	)		(5,732	)
Interest expense		(6,430	)		(2,462	)		(18,525	)		(2,462	)
Total other expense		(6,178	)		(5,732	)
Debt forgiveness		-			1,554			-			1,554
Net loss before taxes		(447,097	)		(7,220	)
Total other expense		(6,430	)		(908	)		(18,525	)		(908	)
Provision for income taxes		-			-
Net loss before taxes		(10,981	)		(16,803	)		(49,731	)		(22,286	)
Loss from Continuing Operations		(447,097	)		(7,220	)
Provision for income taxes					-			-			-
Discontinued operations
Net loss	$	(10,981	)	$	(16,803	)	$	(49,731	)	$	(22,286	)
Loss from discontinued operations		-			(4,912	)
Net Loss Per Common Share – Basic and Diluted	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.00	)
Loss from Discontinued Operations, Net of Tax Benefits		-			(4,912	)
Weighted Average Common Shares Outstanding		9,700,000			9,680,435			9,700,000			9,560,584
Net loss	$	(447,097	)	$	(12,132	)
Net Loss Per Common Share – Basic and Diluted	$	(0.36	)	$	(0.05	)
Weighted Average Common Shares Outstanding		1,253,505			242,500

The accompanying notes are an integral part of these ~~consolidated~~ financial statements.

Table of Contents

BIOSCIENCE NEUTRACEUTICALS, INC.

~~(Formerly~~STATEMENTS ~~JOBLOCATIONMAP~~OF ~~INC.)~~STOCKHOLDERS’ EQUITY

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Nine Months Ended
	Preferred Stock						Common stock				Paid-in		Accumulated
	September 30,
	Shares			Amount			Shares		Amount		Capital		Deficit			Total
	2018			2017
Balance, December 31, 2018		-		$	-			242,516	$	24	$	132,923	$	(318,267	)	$	(185,320	)
Cash Flows from Operating Activities:
Common stock issued for service		-			-			7,000,000		700		421,212		-			421,912
Net loss	$	(49,731	)	$	(22,286	)
Common stock issued for conversion of debt		-			-			800,000		80		7,920		-			8,000
Adjustments to reconcile net loss to net cash used in operating activities:
Net loss for the period		-			-			-		-		-		(447,097	)		(447,097	)
Debt forgiveness		-			(1,554	)
Balance, March 31, 2019		-		$	-			8,042,516	$	804	$	562,055	$	(765,364	)	$	(202,505	)
Changes in operating assets and liabilities:
Inventory		(1,715	)		922
Accounts payable and accrued liabilities		19,812			2,691
Net Cash Used in Operating Activities		(31,634	)		(20,227	)
Cash Flows from Investing Activities:
Acquisition of subsidiary		-			(47,972	)
Net Cash Used in Investing Activities		-			(47,972	)
Cash Flows from Financing Activities:
Loan from related parties		30,436			57,208
Repayments of related party loans		(3,159	)		(8,010	)
Repayments of loans		-			(8,107	)
Proceeds from notes payable		3,957			27,500
Net Cash Provided by Financing Activities		31,234			68,591
Net Change in Cash and Cash Equivalents		(400	)		392
Cash and Cash Equivalents, beginning of period		1,488			-
Cash and Cash Equivalents, end of period	$	1,088		$	392
Supplemental Disclosure Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Non-Cash Disclosure:
Forgiveness of debt by related party to contributed capital	$	-		$	8,273
Accounts payable balances settled by previous owner	$	-		$	6,534

The accompanying notes are an integral part of these consolidated financial statements.

									Additional
	Preferred Stock				Common stock				Paid-in		Accumulated
	Shares		Amount		Shares		Amount		Capital		Deficit			Total

Balance, December 31, 2017		-	$	-		9,700,000	$	970	$	114,215	$	(244,729	)	$	(129,544	)

Net loss for the period		-		-		-		-		-		(12,132	)		(12,132	)

Balance, March 31, 2018		-	$	-		9,700,000	$	970	$	114,215	$	(256,861	)	$	(141,676	)

The accompanying notes are an integral part of these financial statements.

Table of Contents

BIOSCIENCE NEUTRACEUTICALS, INC.

~~(Formerly~~STATEMENTS ~~JOBLOCATIONMAP~~OF ~~INC.)~~CASH FLOWS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2018

(Unaudited)

	Three Months Ended
	March 31,
	2019			2018

Cash Flows from Operating Activities:
Net loss	$	(447,097	)	$	(12,132	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation		421,912			-
Changes in operating assets and liabilities:
Inventory		-			(2,316	)
Prepaid expense		6,000			-
Accounts payable and accrued liabilities		11,937			3,770
Net Cash Used in Operating Activities		(7,248	)		(10,678	)

Cash Flows from Financing Activities:
Loan from related parties		7,248			10,000
Proceeds from notes payable		-			3,957
Net Cash Provided by Financing Activities		7,248			13,957

Net Change in Cash and Cash Equivalents		-			3,279
Cash and Cash Equivalents, beginning of period		-			1,488
Cash and Cash Equivalents, end of period	$	-		$	4,767

Supplemental Disclosure Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Non Cash Investing and Financing Activities
Common stock issued for conversion of debt	$	8,000		$	-

The accompanying notes are an integral part of these financial statements.

Table of Contents

BIOSCIENCE NEUTRACEUTICALS, INC.

NOTES TO THE FINANCIAL STATEMENTS

March 31, 2019

(Unaudited)

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

Organization, Nature of Business and Trade Name

Bioscience Neutraceuticals, Inc. (the Company) was incorporated in the State of Nevada on June 15, 2010 under the name JobLocationMap Inc. ~~Bioscience Neutraceuticals, Inc.’s principal business objective is developing and marketing an online map application.~~ The Company is located at 500 North Michigan Avenue #600, Chicago, Illinois.

The Company’s activities are subject to significant risks and uncertainties including failing to secure additional funding to operationalize the Company’s ~~online~~future ~~map~~operations. ~~application~~The ~~before~~Company ~~another~~is ~~company~~currently ~~develops~~evaluating aand ~~similar~~reviewing ~~app~~the future course of business.

~~Recent~~Disposal ~~Developments~~of business

On ~~July~~October 101, ~~2017~~2018, the Company ~~acquired~~disposed ~~all~~ of ~~the~~its ~~shares~~previous ofonline ~~Bio~~application ~~Health Products Inc~~business. aThe ~~Nevada~~change ~~corporation, in exchange for 200,000 shares~~ of the ~~Company’s~~business ~~common~~qualified ~~stock,~~as ~~whereby Bio Health Products Inc. became~~ a ~~wholly~~discontinued ~~owned~~operation ~~subsidiary~~ of the Company. ~~Bio~~and ~~Health~~accordingly, ~~Products~~the ~~Inc.~~Company ~~had~~has ~~previously~~excluded ~~acquired~~results ~~the assets~~ of ~~Essential~~the ~~Oils,~~operations afrom ~~sole~~its ~~proprietorship.~~Statements ~~Bio~~of ~~Health~~Operations ~~Products~~to ~~Inc.~~present ~~was~~this ~~owned~~business byin ~~Liang~~discontinued ~~Chen, the CEO of the Company~~operations.

AsReverse ~~these~~Stock transactions are between entities under common control, the Company has reported the results of operations for the period in a manner similar to a pooling of interests and has consolidated financial results since the initial date in which the above companies were under common control. Assets and liabilities were combined on their carrying values and no recognition of goodwill was made. The Company has presented earnings per share based on the new parent company shares issued to the former shareholders of the Company.Split

On January 18, 2019, a majority of our shareholders approved a reverse stock split on a basis of 40 old shares for one (1) new share of our issued and outstanding common stock. The reverse split has been reviewed by the Financial Industry Regulatory Authority and has been approved for filing with an effective date of February 7, 2019. All share and per share information in these financial statements retroactively reflect this stock distribution.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of significant accounting policies of the Company is presented to assist in understanding the Company’s consolidated financial statements. The accounting policies presented in these footnotes conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the accompanying financial statements. These financial statements and notes are representations of the Company’s management who are responsible for their integrity and objectivity. The Company has not realized revenues from its planned principal business purpose.

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the ~~nine~~three months ended ~~September~~March 3031, ~~2018~~2019, are not necessarily indicative of the results ofthat ~~operations~~may be expected for the ~~full~~fiscal year. ~~These~~ending ~~consolidated~~December ~~financial~~31, ~~statements~~2019. ~~and~~For ~~related~~further ~~footnotes~~information, ~~should~~refer beto ~~read in conjunction with~~ the financial statements and footnotes thereto included in the ~~Company~~Corporation’s ~~Annual~~filed ~~Report on~~ Form ~~10K~~10-K for the year ended December 31, ~~2017, filed with the Securities and Exchange Commission~~2018.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its subsidiaries. Intercompany transactions and balances have been eliminated.

6 Table of Contents

Use of Estimates

The preparation of financial statements in accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. A change in managements’ estimates or assumptions could have a material impact on Bioscience Neutraceuticals, Inc.’s financial condition and results of operations during the period in which such changes occurred. Actual results could differ from those estimates. Bioscience Neutraceuticals, Inc.’s financial statements reflect all adjustments that management believes are necessary for the fair presentation of their financial condition and results of operations for the periods presented.

~~Cash~~7 ~~and~~Table ~~Cash~~of ~~Equivalents~~Contents

For purposes of the statement of cash flows, the Company considers all short-term debt securities purchased with maturity of three months or less to be cash equivalents.

Revenue Recognition

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

· identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied.

Under these criteria, this generally means that the Company recognizes revenue when its products are delivered to customers in accordance with the sales terms.

Cost of Goods Sold

Cost of goods sold includes the following expenses; inventory and various expenses related to sell the products through third party services.

Inventory

The Company’s inventory consists of oil products. All inventory is finished goods. Inventories are stated at the lower of cost or market value. Inventory is stored off-site and held by a third party. The Company utilizes last-in first-out for inventory items held. Items determined to be obsolete are reserved for. The Company provides for the possible inability to sell its inventories by providing an excess inventory reserve. As at September 30, 2018, the Company determined that no reserve was required.

NOTE 3 – GOING CONCERN

The Company’s ~~consolidated~~ financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern.

Under the going concern assumption, an entity is ordinarily viewed as continuing in business for the foreseeable future with neither the intention nor the necessity of liquidation, ceasing trading, or seeking protection from creditors pursuant to laws or regulations. Accordingly, assets and liabilities are recorded on the basis that the entity will be able to realize its assets and discharge its liabilities in the normal course of business.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the Nature of Business and Trade Name paragraph and eventually attain profitable operations. The accompanying financial statements do not include any adjustments that may be necessary if the Company is unable to continue as a going concern.

7 Table of Contents

During the next year, the Company’s foreseeable cash requirements will relate to continual development of the operations of its business, maintaining its good standing and making the requisite filings with the Securities and Exchange Commission, and the payment of expenses associated with research and development. The Company may experience a cash shortfall and be required to raise additional capital.

Historically, it has mostly relied upon internally generated funds and funds from the sale of shares of stock to finance its operations and growth. Management may raise additional capital through future public or private offerings of the Company’s stock or through loans from private investors, although there can be no assurance that it will be able to obtain such financing. The Company’s failure to do so could have a material and adverse effect upon it and its shareholders.

In the past year, the Company funded operations by using cash proceeds received through the issuance of common stock and loan from related party. For the coming year, the Company plans to continue to fund the Company through debt and securities sales and issuances until the company generates enough revenues through the operations as stated above.

NOTE 4 – ~~EQUITY~~NOTE PAYABLE

On June 9, 2017, the Company issued note payable of $7,500 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand.

On August 14, 2017, the Company issued note payable of $20,000 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand.

On March 31, 2018, the Company issued note payable of $3,957 to a third party. The note is a 57% interest bearing promissory note that is payable on March 31, 2023.

As of March 31, 2019, and December 31, 2018, the Company owed notes payable of $27,500 and $27,500, Long-term note payable of $3,957 and $0 and accrued interest of $20,726 and $17,457, respectively. During the three months ended March 31, 2019 and 2018, the Company recognized interest expense of $3,268 and $2,710, respectively.

NOTE 5 – CONVERTIBLE NOTE PAYABLE

On December 31, 2017, the Company issued a convertible note of $4,875 with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $4,875 and amortized $4,875 for the year ended December 31, 2017. During the three months ended March 31, 2019, the convertible note of $4,000 was converted into 400,000 shares of common stock.

On December 31, 2017, the Company issued a convertible note of $6,803 with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $6,803 and amortized $6,803 for the year ended December 31, 2017. During the three months ended March 31, 2019, the convertible note of $4,000 was converted into 400,000 shares of common stock.

As of March 31, 2019, and December 31, 2018, the Company owed convertible notes payable of $14,878 and $22,878 and accrued interest of $15,200 and $12,290, respectively. During the three months ended March 31, 2019 and 2018, the Company recognized interest expense of $2,910 and $3,022, respectively.

Table of Contents

NOTE 6 – EQUITY

The Company has authorized 100,000,000 shares of common stock with a par value of $0.0001 and 50,000,000 shares of preferred stock with a par value of $0.0001.

Preferred stock

As of ~~September~~March 3031, ~~2018~~2019, and December 31, ~~2017~~2018, there was no shares issued and outstanding.

Common stock

OnDuring ~~July~~the 10three months ended March 31, ~~2017~~2019, the Company issued ~~200~~8,~~000~~042,516 shares ~~to acquire all~~ of ~~the~~common ~~shares~~stock ofas ~~Bio Health Products Inc. (Note 1).~~follows;

9 ·7,~~700~~000,000 shares ofto ~~common~~our ~~stock~~CEO ~~were~~for ~~issued~~compensation ·800,000 ~~and~~shares ~~outstanding~~for asconversion of ~~September~~debt ~~30,~~of ~~2018 and December 31~~$8, ~~2017.~~000

~~NOTE~~8,042,516 5and –242,516 ~~NOTE~~shares ~~PAYABLE~~of common stock were issued and outstanding as of March 31, 2019 and December 31, 2018.

On June 9, 2017, the Company issued note payable of $7,500 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand. During the nine months ended September 30, 2018, the Company recognized interest expense of $2,244.

On August 14, 2017, the Company issued note payable of $20,000 to a third party. The note is a 40 % interest bearing promissory note that is payable on demand. During the nine months ended September 30, 2018, the Company recognized interest expense of $5,984.

On March 31, 2018, the Company issued note payable of $3,957 to a third party. The note is a 57% interest bearing promissory note that is payable on March 31, 2023. During the nine months ended September 30, 2018, the Company recognized interest expense of $1,131.

As of September 30, 2018, and December 31, 2017, the Company owed notes payable of $27,500 and $27,500, Long-term note payable of $3,957 and $0 and accrued interest of $14,117 and $4,758, respectively.

8 Table of Contents

NOTE 6 – CONVERTIBLE NOTE PAYABLE

On December 31, 2017, the Company issued a convertible note of $4,875 with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $4,875 and amortized $4,875 for the year ended December 31, 2017. As of September 30, 2018, and December 31, 2017, the Company had a convertible note of $4,875 and accrued interest of $2,086 and $8, respectively. During the nine months ended September 30, 2018, the Company recognized interest expense of $2,078.

On December 31, 2017, the Company issued a convertible note of $6,803 with a conversion price of $0.01. The convertible note is unsecured, bears interest at 57% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $6,803 and amortized $6,803 for the year ended December 31, 2017. As of September 30, 2018, and December 31, 2017, the Company had a convertible note of $6,803 and accrued interest of $2,911 and $11, respectively. During the nine months ended September 30, 2018, the Company recognized interest expense of $2,900.

On December 31, 2017, the Company issued a convertible note of $11,200 with a conversion price of $0.005. The convertible note is unsecured, bears interest at 50% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $11,200 and amortized $11,200 for the year ended December 31, 2017. As of September 30, 2018, and December 31, 2017, the Company had a convertible note of $11,200 and accrued interest of $4,203 and $15, respectively. During the nine months ended September 30, 2018, the Company recognized interest expense of $4,188.

As of September 30, 2018, and December 31, 2017, the Company owed convertible notes payable of $22,877 and accrued interest of $9,200 and $34, respectively

NOTE 7 – RELATED TRANSACTIONS

Due to related parties

During the ~~nine~~three months ended ~~September~~March 3031, 2019 and 2018, the Company received loans from the Related Party Director of $307,~~436~~248 and $10,000 to pay for operating expenses ~~and repaid $3~~,~~159~~ respectively.

~~During~~As ~~the~~of ~~nine~~March ~~months ended September 30~~31, ~~2017,~~2019 ~~the~~and ~~Company~~December ~~received loans from the previous Related Party Directors of $10~~31,~~834~~ ~~to pay for operating expenses. Prior to the sale of their shares~~2018, ~~the~~related ~~loans~~party toloan ~~the~~payable ~~two~~outstanding ~~previous~~is ~~Related Party Directors were~~ $~~21,~~107~~. Upon completion of the share purchase agreements between the two previous Related Party Directors~~,420 and ~~the new CEO, the~~ $14100,~~807 was forgiven~~172, ~~and recorded to additional paid-in capital~~respectively.

~~During~~NOTE ~~the~~8 ~~nine~~– ~~months~~DISCONTINUED ~~ended September 30, 2017, the new CEO loaned the Company $49,825 for operational expenses and acquisition of subsidiary.~~OPERATIONS

During the ~~nine~~year ~~months~~ ended ~~September~~December 3031, ~~2017~~2018, the ~~former~~Company ~~officer~~disposed of online map application business. The change of the ~~subsidiary~~business ~~advanced~~qualified ~~$1,082~~as ~~for~~a ~~operational~~discontinued ~~expenses~~operation ~~and~~of ~~repaid~~the $8Company and accordingly,~~009~~ the Company has excluded results of the operations from its Statements of Operations to present this business in discontinued operations.

AsThe offollowing ~~September~~table ~~30,~~shows ~~2018~~the ~~and~~results ~~December~~of ~~31,~~operations ~~2017,~~which ~~related~~are ~~party~~included ~~loan~~in ~~payable~~the ~~outstanding~~gain isfrom ~~$102,556~~discontinued ~~and $75,279, respectively.~~operations:

NOTE 8 – SUBSEQUENT EVENTS

	Three Months Ended
	March 31,
	2019		2018
Revenue	$	-		2,287
Cost of goods		-		(4,754	)
Gross profit		-		(2,467	)
General and administration		-		2,195
Professional		-		250
Operating loss		-		(4,912	)
Income tax provision		-		-
Loss from discontinued operations, net of tax		-		(4,912	)

NOTE 9 – SUBSEQUENT EVENTS

Management has evaluated potential subsequent events through the date the financial statements were issued. Based on our evaluation no events have occurred that require disclosure.

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition or Plan of Operation

FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Bioscience Neutraceuticals, Inc.. and our wholly owned subsidiary, Bio Health Products Inc., a Nevada corporation, unless otherwise indicated.

General Overview

We were incorporated under the laws of the State of Nevada on June 15, 2010 under the name JobLocationMap Inc. Our principal business objective ~~since incorporation~~ was developing and marketing an online map application, which has since been discontinued.

On July 10, 2017, we acquired all of the shares of Bio Health Products Inc. a Nevada corporation, in exchange for 200,000 shares of our common stock, whereby Bio Health Products became a wholly owned subsidiary of our company. Bio Health Products Inc. had ~~previous~~previously acquired the assets of Essential Oils, a sole proprietorship. Bio Health Products Inc. was owned by Liang Chen, the CEO of our company.

With the acquisition of Bio Health Products (“BHP”) our company ischanged ~~changing~~ its focus to the sale of high end pure organic oils also called “Essential Oils”., Wewhich ~~now~~has ~~operate~~since ~~the~~been ~~website www~~discontinued.~~bestaromaoils.com that was acquired as part of the BHP transaction.~~

On November 14, 2018, our board of directors approved an agreement and plan of merger to merge with our wholly-owned subsidiary, Bioscience Neutraceuticals, Inc. a Nevada corporation, to effect a name change from JobLocationMap, Inc. to Bioscience Neutraceuticals, Inc. Our company remained the surviving entity. Bioscience Neutraceuticals, Inc. was formed solely for the change of name. Articles of Merger to effect the merger and change of name were filed with the Nevada Secretary of State and the change of name was approved by the Financial Industry Regulatory Authority (FINRA) with an effective date of December 12, 2018.

Our address is 500 North Michigan Avenue, #600, Chicago, IL 60611. Our telephone number is (773) 236-8132.

We have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

Table of Contents

Our Current Business

~~Our~~The ~~business~~Company is ~~focused~~currently onevaluating and reviewing the ~~high~~future ~~end~~course ~~pure~~of ~~organic~~business ~~oils~~and ~~also~~evaluating ~~called~~potential ~~“Essential~~business ~~Oils~~opportunities in the health science sector.”

BHP orders pure oils wholesale from suppliers and repackages and rebrands them to sell to end consumers. It specializes in a few key product lines currently and has built up its branding by marketing to sell niche lifestyle products that are branded as being very pure and only available in high concentration.

Essential oils can be distilled from leaves, barks, roots and other parts of a plant. They are said therefore to contain the true essence of these plants and can be used then to provide psychological and physical therapeutic benefits. Such oils have been used for thousands of years but it was only in the 1970s to 1980s that these oils started to become a major part of alternative health therapy around the world. Since then people have also started creating cleaners as well as pet remedies from these oils. Essential oils are also widely utilized in cleaning & home products owing to their superior antibacterial and antiseptic properties. Customers are keen on specialized products as various applications require specific characteristics and ingredients.

These naturally derived oils have no detrimental side effect unlike most conventional drugs and medicines, which is a major driving factor for the essential oil market. Increasing demand for natural personal care products and pleasant aromatic cleaning agents is expected to foster the industry growth in these applications. Growing need for aromatic flavors and fragrances in cosmetics, perfumes, as well as spa and relaxation applications is expected to fuel demand in upcoming years.

Most of these oils are created by large farm distribution centers which in turn send their products to their industrial partners or to distributors to repackage, brand and also to sometimes dilute down these oils for sale at a retail level.

Oils can also be used individually or blended to produce additional uses. Single oils for example can be used for arthritis, muscle pain, colds, diarrhea and blends can be used for the treatment of acne, boost immunity and anti-aging

BHP’s product line consists of:

· Tea Tree Oil is perfect for acne treatment, skin tag removal, dry scalp and dandruff, toe and foot fungus, wart removal, and skin oil remover. · Eucalyptus Oil will act as a nasal decongestant to clear sinuses to allow for easier breathing. It will open up air passages so a good comfortable night rest is possible. · Castor Oil is good for hair growth and to grow and strengthen eyelashes and eyebrows. It can also be used as a facial moisturizer and in skin care · Rosehip Oil is for skin and facial care, helps to reduces wrinkles and fine lines and has good anti-aging properties · Lemon Oil’s strong citrus scent works well in aromatherapy diffusers and can also be used as a natural household cleaner and disinfectant, and in DIY skin care recipes · Cinnamon Oil is best used for aromatherapy and muscle pain relief. It therefore works well for massages and in anxiety and depression relief · Cedarwood Oil, · Lemongrass Oil can be used for aromatherapy and as a fragrance additive. It also has anti-inflammatory, anti-fungal and bug repellent properties. · Emu Oil will help regenerate skin to provide a youthful appearance. It can be used as a facial toner and it will improve damage from eczema, psoriasis, burn scars, surgical scars, redness, age spots, sun spots, sores, and can also be used to help moisturize dry skin.

11 Table of Contents

Results of Operations

The following summary of our operations should be read in conjunction with our unaudited consolidated financial statements for the three ~~and nine~~ months ended ~~September~~March 3031, ~~2018~~2019 and ~~2016~~2018.

Three Months Ended ~~September~~March 3031, ~~2018~~2019 Compared to Three Months Ended ~~September~~March 3031, ~~2017~~2018

	For the Three Months Ended
	Three Months Ended
	September 30,
	March 31,
	2018			2017			Change
	2019			2018			Change
Revenue	$	~~1,693~~-		$	~~4,318~~-		$	~~(2,625~~-	)
Cost of Goods Sold		1,859			3,518			(1,659	)
Gross Profit		(166	)		800			(966	)
Operating Expenses								-
General and administrative expenses		~~1,435~~382			~~1,495~~-			~~(60~~382	)
Professional fees		218,~~950~~625			151,~~200~~488			~~(12~~17,~~250~~137	)
Other income (expense)		(6,430	)		(908	)		(5,522	)
Stock based compensation		421,912			-			421,912
Net Loss	$	(10,981	)	$	(16,803	)	$	5,822
Other income (expense)		(6,178	)		(5,732	)		(446	)
Loss from discontinued operations		-			(4,912	)		4,912
Net Loss	$	(447,097	)	$	(12,132	)	$	(434,965	)

We recognized no revenues ~~of $1,693~~ for the three months ended ~~September~~March 3031, ~~2018,~~2019 ~~compared~~and ~~to $4,318 for the same period in 2017.~~2018

Our operating expenses, for the three months ended ~~September~~March 3031, ~~2018~~2019 were $4440,~~385~~919 compared to $161,~~695~~488 for the same period in ~~2017~~2018. The ~~decrease~~increase in operating expenses was primarily as a result of astock-based ~~decrease~~compensation into ~~professional~~our ~~fees~~CEO.

We ~~incurred~~recorded aloss ~~net~~from ~~loss~~discontinued operations of $~~10,981~~0 and $164,~~803~~912 for the three months ended ~~September~~March 3031, ~~2018~~2019 and ~~2017~~2018, respectively.

~~Nine~~We ~~Months~~incurred ~~Ended~~a ~~September~~net 30loss of $447,097 ~~2018~~and ~~Compared~~$12,132 tofor ~~Nine~~the ~~Months~~three ~~Ended~~months ~~September~~ended 30March 31, ~~2017~~2019 and March 31, 2018, respectively.

	For the Nine Months Ended
	September 30,
	2018			2017			Change
Revenue	$	6,163		$	4,318		$	1,845
Cost of Goods Sold		8,257			3,518			4,739
Gross Profit		(2,094	)		800			(2,894	)
Operating Expenses								-
General and administrative expenses		5,905			2,728			3,177
Professional fees		23,207			19,450			3,757
Other income (expense)		(18,525	)		(908	)		(17,617	)
Net Loss	$	(49,731	)	$	(22,286	)	$	(27,445	)

We recognized revenues of $6,163 for the nine months ended September 30, 2018, compared to $4,318 for the same period in 2017.

Our operating expenses, for the nine months ended September 30, 2018 were $29,112 compared to $22,178 for the same period in 2017. The increase in operating expenses was primarily as a result of an increase in professional fees.

We incurred a net loss of $49,731 and $22,286 for the nine months ended September 30, 2018 and 2017, respectively.

12 Table of Contents

Liquidity and Capital Resources

Working Capital

	September 30,			December 31,
	March 31,			December 31,
	2018			2017
	2019			2018
Cash	$	~~1,088~~-		$	~~1,488~~-
Current Assets	$	~~6,004~~-		$	46,~~689~~000
Current Liabilities	$	~~181~~198,~~322~~548		$	~~134~~187,~~233~~363
Working Capital	$	(~~175~~198,~~318~~548	)	$	(~~129~~181,~~544~~363	)

Table of Contents

Cash Flows

	For the Nine Months Ended
	Three Months Ended
	September 30,
	March 31,
	2018			2017
	2019			2018
Cash Flows used in Operating Activities	$	(317,~~634~~248	)	$	(2010,~~227~~678	)
Cash Flows used in Investing Activities		-			(47,972	)
Cash Flows from Financing Activities		7,248			13,957
Cash Flows from Financing Activities		31,234			68,591
Net Change in Cash During Period	$	-		$	3,279
Net Change in Cash During Period	$	(400	)	$	392

As at ~~September~~March 3031, ~~2018~~2019 our company’s cash balance was $~~1,088~~0 and total assets were $~~6,004~~0. As at December 31, ~~2017~~2018, our company’s cash balance was $~~1,488~~0 and total assets were $46,~~689~~000.

As at ~~September~~March 3031, ~~2018~~2019, our company had total liabilities of $~~185~~202,~~279~~505, compared with total liabilities of $~~134~~191,~~233~~320 as at December 31, ~~2017~~2018.

As at ~~September~~March 3031, ~~2018~~2019, our company had a working capital deficiency of $~~175~~198,~~318~~548 compared with a working capital deficiency of $~~129~~181,~~544~~363 as at December 31, ~~2017~~2018. The increase in working capital deficit was primarily ~~attributed~~due to ana ~~increase~~decrease in ~~due~~prepaid toexpense ~~related~~and ~~parties~~an ~~and~~increase in accounts payable and accrued liabilities and due to related parties.

Cash Flow from Operating Activities

During the three months ended ~~September~~March 3031, ~~2018~~2019, our company used $317,~~634~~248 in cash from operating activities, compared to $2010,~~227~~678 cash used in operating activities during the three months ended ~~September~~March 3031, ~~2017~~2018. The cash used from operating activities for the three months ended ~~September~~March 3031, ~~2018~~2019 was attributed to a net loss of $49447,~~731~~097 ,and was offset by astock-based compensation of $421,912 and change in ~~operation~~operating assets and liabilities of $1817,~~097~~937.

Cash Flow from Investing Activities

During the three months ended ~~September~~March 3031, 2019 and 2018, our company ~~used~~did $0not inhave investing activities ~~compared to $47,972 used in investing activities during the three months ended September 30, 2017.~~

Cash Flow from Financing Activities

During the three months ended ~~September~~March 3031, ~~2018~~2019 our company received $317,~~234~~248 from ~~financing~~loan ~~activities compared to $68,591 received~~ from ~~financing~~related ~~activities~~parties ~~during~~compared ~~the~~to ~~three months ended September 30, 2017. The cash flow for financing activities for the three months ended September 30, 2018, was a result of~~ $3010,~~436~~000 from loan from related parties, and $3,957 from ~~proceeds from~~ notes payable ~~and~~during ~~$3,159~~the inthree ~~repayment~~months ofended ~~related~~March ~~party~~31, ~~loans~~2018.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

13 Table of Contents

Critical Accounting Policies

We prepare our interim financial statements in conformity with GAAP, which requires management to make certain estimates and apply judgments. We base our estimates and judgments on historical experience, current trends and other factors that management believes to be important at the time the financial statements are prepared. On a regular basis, we review our accounting policies and how they are applied and disclosed in our interim financial statements.

While we believe that the historical experience, current trends and other factors considered support the preparation of our interim financial statements in conformity with GAAP, actual results could differ from our estimates and such differences could be material.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation Of Disclosure Controls And Procedures

As required by Rule 13a-15/15d-15 under the Securities and Exchange Act of 1934,as amended (the "Exchange Act"), as of ~~September~~March 3031, ~~2018~~2019, we have carried out an evaluation of the effectiveness of the design and operation of our Company's disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our Company's management, our Chief Executive Officer and Chief Financial Officer (our Principal Executive Officer and Principal Accounting Officer). Based upon the results of that evaluation, our management has concluded that, as of ~~September~~March 3031, ~~2018~~2019, our Company's disclosure controls and procedures were effective and provide reasonable assurance that material information related to our Company required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management to allow timely decisions on required disclosure.

Management's Report On Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control system is designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:

· Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; · Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and · Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.

Management assessed the effectiveness of our internal control over financial reporting as of ~~September~~March 3031, ~~2018~~2019. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in INTERNAL CONTROL -- INTEGRATED FRAMEWORK.

Our management concluded that, as of ~~September~~March 3031, ~~2018~~2019, our internal control over financial reporting was not effective based on the criteria in INTERNAL CONTROL -- INTEGRATED FRAMEWORK issued by the COSO.

This quarterly report does not include an attestation report of the Company's independent registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's independent registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management's report in this quarterly report.

Changes In Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation described above during the first quarter ended ~~September~~March 3031, ~~2018~~2019 that has materially affected or is reasonably likely to materially affect our internal controls over financial reporting.

1413 Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party and which would reasonably be likely to have a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or a witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

15 Table of Contents

Item 6. Exhibits

Exhibit Number		Description
ExhibitNumber		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1*		Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101**		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

~~______~~ _________

* Filed herewith. ** Furnished herewith.

1614 Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BIOSCIENCE NEUTRACEUTICALS, INC.
		(Registrant)
Dated: January 8, 2019		/s/ Liang Chen
Dated: May 15, 2019		/s/ Liang Chen
		Liang Chen
		Chief Executive Officer, Chief Financial Officer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

1715

Filing Compare · BIOSCIENCE NEUTRACEUTICALS, INC.